Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Assunto principal
Intervalo de ano de publicação
1.
J Med Genet ; 43(4): 347-52, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16227523

RESUMO

BACKGROUND: Fabry disease is a rare X linked lysosomal storage disorder resulting from deficiency of alpha-galactosidase A activity. Although the severity of clinical features in male patients is well described, only recently have studies reported the high prevalence of disabling clinical features in heterozygous females. AIMS: This study sets out to examine the clinical features and natural history of Fabry disease in further detail in a large group of female patients. METHODS: Data were obtained from 303 females enrolled in the Fabry Outcome Survey. Pain was assessed using the Brief Pain Inventory, and health related quality of life (HRQoL) was assessed using the European Quality of Life Questionnaire. A modified version of the Mainz Severity Score Index was also applied. Data on left ventricular mass (LVM) index, mean ventricular wall thickness, and glomerular filtration rate (GFR) were used to assess cardiac and renal involvement. RESULTS: The most commonly reported clinical features in females were neurological (77%) and cardiac (59%). A history of renal involvement was recorded in 40% of cases. Neurological features were the earliest to develop (mean age: 16 years), whereas cardiac (mean age: 33.5 years) and renal (mean age: 37.3 years) features developed later. LVM index increased exponentially with age. In addition, age was negatively correlated with estimated GFR and HRQoL. CONCLUSIONS: Females with Fabry disease report important age related clinical features and clinical investigation demonstrates evidence of disease progression. This study highlights the importance of careful and longitudinal assessment of female heterozygote patients with Fabry disease.


Assuntos
Doença de Fabry/diagnóstico , Adolescente , Adulto , Fatores Etários , Idoso , Progressão da Doença , Enzimas/metabolismo , Doença de Fabry/tratamento farmacológico , Doença de Fabry/epidemiologia , Feminino , Inquéritos Epidemiológicos , Ventrículos do Coração/patologia , Heterozigoto , Humanos , Isoenzimas/uso terapêutico , Pessoa de Meia-Idade , Medição da Dor , Proteinúria/diagnóstico , Qualidade de Vida , Resultado do Tratamento , Função Ventricular Esquerda , alfa-Galactosidase/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA